Navitoclax: Preliminary Phase IIa data

Preliminary data from 14 evaluable patients in the Phase IIa portion of an open-label Phase I/IIa trial showed that once-daily 325 mg oral navitoclax produced 4 cases of stable disease. Serious advers...